We herewith enclose the Unaudited Financial Results for the Quarter ended June 30, 2026 as approved by the Board of Directors in its meeting held on August 11, 2026.

BAFNA PHARMACEUTICALS LIMITED REGD. OFFICE: “BAFNA TOWERS”, NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com CIN: L24294TN1995PLCO30698 Date: August 11, 2026 BSE Limited, National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Mumbai - 400001. Bandra East, Mumbai – 400051. Scrip Code: 532989 Scrip Code: BAFNAPH Dear Sir/Madam, Subject: Outcome of Board Meeting held on August 11, 2026 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors in their meeting held Today (i.e) August 11, 2026, inter-alia considered and approved the following: i). The Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors of the Company, for the First Quarter ended June 30, 2026 as recommended by the Audit Committee. Accordingly, pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, the Unaudited Financial Results of the Company for the quarter ended June 30, 2026 along with the Limited Review Report, are enclosed herewith. ii). Annual General Meeting: The 31st Annual General Meeting (AGM) of the Company will be held on Friday, September 11, 2026, at 10:00 A.M (IST) through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). iii). Book Closure: The Register of Members and Share Transfer Books of the company will remain closed from Saturday, September 05, 2026 to Friday, September 11, 2026 (both days inclusive), pursuant to Section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Factory: No.147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052, TN, India Phone: 9445149001 Email: factory1@bafnapharma.com BAFNA PHARMACEUTICALS LIMITED REGD. OFFICE: “BAFNA TOWERS”, NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com CIN: L24294TN1995PLCO30698 iv). Cut-Off Date: The Cut-Off date for the purpose of determining eligibility of members for voting at the 31st AGM shall be Friday, September 04, 2026. The Meeting of the Board of Directors commenced at 02.30 P.M and concluded at 04.00 P.M. We request you to take the documents and information on record. Thanking You. For BAFNA PHARMACEUTICALS LIMITED Mohanachandran A Company Secretary & Compliance Officer Enclosed: As Above Factory: No.147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052, TN, India Phone: 9445149001 Email: factory1@bafnapharma.com BAFNA PHARMACEUTICALS LTD CIN: L24294TN1995PLC030698 Corporate Office and Registered Office: Bafna Towers, New No. 68, Old No 299, Tambu Chetty Street, Chennai-600001 (Tamil Nadu) Email : cs@bafnapharma.com, Web: www.bafnapharma.com Statement of unaudited Financial Results for the Quarter Ended 30th June 2026 (INR in Lakhs except as Stated) Quarter Ended Year Ended Particulars 30th June 2026 31st March 2026 30th June 2025 31st March 2026 (Unaudited) (Audited) (Unaudited) Audited) 1 Revenue from Operations 2,658.32 4,223.93 3,462.40 15,061.74 Other Income 191.10 176.16 59.56 475.63 2 Total Income 2,849.42 4,400.09 3,521.96 15,537.37 EXPENSES Cost of Material Consumed 1,431.50 2,139.30 1,755.78 8,213.53 Manufacturing Expenses 488.75 537.28 507.96 2,050.82 Change in Inventories of Work-in-Progress and Finished Goods (I 70.44) 297.11 (21.96) (15.96) Employee benefits expenses 561.63 544.33 563.99 2,191.89 Finance cost 93.70 102.90 90.54 366.1 J Depreciation and Amortization expense 178 07 165.99 136.99 607.26 Other expenses 258.70 351.23 149.77 1,026.70 3 Total Expenses 2,841.91 4,138.14 3,183.07 14,440.35 4 Profit/(Loss) before Exceptional Items & tax (2-3) 7.51 261.95 338.89 1,097.02 5 Exceptional Items - - - - 6 Profit I (Loss) before Tax ( 4-5) 7.51 261.95 338.89 1,097.02 7 Tax Expense - Relating to Previous Periods - (12.96) - (12.96) 8 Profit/ (Loss) for the Period (6-7) 7.51 274.91 338.89 1,109.98 9 Other Comprehensive Income 6.08 38.20 ( 4.62) 24.33 IO Total Comprehensive Income for the period (8+9) 13.59 313.11 334.27 1,134.31 11 Paid up Share Capital (Face Value ofINR IO each) 2,365.63 2,365.63 2,365.63 2,365.63 12 Other Equity as per the Balance Sheet 7,249.32 13 Earnings Per Equity Share (not annualised) Basic (in INR) 0.03 J.16 1.43 4.69 Diluted (in INR) 0.03 1.16 1.43 4.69 Notes 1 The above unaudited financial results for the quarter ended 30th June 2026 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at their respective meetings held on l l th August 2026. The Statutory Auditors have conducted a "Limited Review" of these financial results in terms of Regulation 33 ofSEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2 The figures for the quarter ended 31st March 2026 are the balancing figures between the audited figures in respect of the full financial year ended 31st March 2026 and the unaudited published figures for nine months ended 31st December 2025.The figures for the corresponding previous periods have been regrouped and reclassified, wherever necessary, to make them comparable. 3 The above unaudited financial results have been prepared in accordance with Indian Accounting Standard 34 "Interim Financal Reporting" (Ind AS 34") precribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. 4 Company's business relates to the manufacturing of pharmaceuticals formations, which in context of Indian Accounting Standards 108 (Ind AS I 08) as notified under Section 133 of the Companies Act, 2013 is considered as the only segment. 5 The Company has received orders from the Goods and Services Tax authorities, including a demand order raising a GST liability amounting to INR 235.47 Lakhs and another order issued by the Joint Commissioner towards recovery of GST refunds availed during earlier years amounting to INR 331.09 Lakhs, along with applicable interest and penalty. The Company has preferred an appeal against the GST demand of INR 235.47 Lakhs. In respect of the recovery of GST refunds, the Company has obtained a stay for the amount of INR 331.09 Lakhs based on the writ petition before the Honorable Madras High Court. Based on the underlying facts of the cases, applicable legal provisions, judicial precedents and prevailing industry practices, the Company is confident of prevailing against the positions adopted by the GST authorities and accordingly, does not anticipate any adverse financial outcome. Ph""'"'"",'l'"' Fm· Baro, Place : Chennai "'"'"'"' Date : 11th August, 2026 ..f l:"-~ ~~VYAcf Co'.. I ~~ ~ ~~~~ ~ I Whol~ e T ~ im e Director Q:) For - n... C,~ r- (DIN: 02714329) Chartered Accountants Independent Auditor’s Review Report on Unaudited Quarterly Financial Results of Bafna Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 The Board of Directors Bafna Pharmaceuticals Limited 1. We have reviewed the accompanying Statement of Unaudited Financial Results of Bafna Pharmaceuticals Limited (the “Company”), for the quarter ended 30th June 2026 (the “Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable. 2. The Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement pri [Showing first 8,000 characters — download PDF for full document]